USPTO approves patent for Avisena's system for managing accounts receivables

NewsGuard 100/100 Score

Avisena, a provider of revenue cycle management software and services for physician practices, today announced that the United States Patent and Trademark Office has approved a patent for the company's "system for managing accounts receivables."

“This patent approval is a major milestone in our company's efforts to help physicians decrease denials, improve collections and better manage cash flow in an industry marked by complicated revenue cycles”

The patent covers the proprietary technology and methodology of the company's platform, which simplifies physicians' complex revenue cycles and helps them to efficiently managing their accounts receivables. Combining a robust rules engine with a vast database of industry intelligence, the Avisena solution helps to ensure physician submit clean claims to insurers on the first pass, estimates the true value of a claim and forecasts reimbursement amounts that result in efficient and timely collection of receivables.

"This patent approval is a major milestone in our company's efforts to help physicians decrease denials, improve collections and better manage cash flow in an industry marked by complicated revenue cycles," said Mike Maseda, Avisena's president and CEO. "Combining robust software with billing, coding and collections expertise, we automate back-office processes, help physicians improve practice productivity and achieve results that improve financial performance."

Source:

Avisena

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass Spectrometry